San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

The LORETTA trial evaluates tamoxifen monotherapy as a potential nonsurgical option for carefully selected patients with low-risk, estrogen receptor–positive/HER2-negative ductal carcinoma in situ. Read More ›

Discover how combining preoperative radiation with immunotherapy is revolutionizing treatment for high-risk, HR-positive/HER2-negative breast cancer in a groundbreaking clinical trial. Read More ›

New research reveals that preoperative breast MRI may not improve outcomes for early-stage breast cancer patients, challenging its routine use in surgical planning. Read More ›

New insights reveal patient preferences for oral endocrine therapy over intramuscular options in metastatic breast cancer, emphasizing the need for personalized treatment decisions. Read More ›

New research highlights critical gaps in ESR1 mutation testing for estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer, emphasizing the need for increased use of blood-based circulating tumor DNA methods to improve treatment outcomes. Read More ›

The ADELA trial investigates the potential of combining elacestrant with everolimus to overcome resistance and improve outcomes in ESR1-mutated, estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. Read More ›

Discover the latest breakthroughs in breast cancer treatment, as innovative strategies to overcome resistance to CDK inhibitors are explored, and new therapeutic possibilities are unlocked. Read More ›

Explore cutting-edge strategies and emerging therapies designed to tackle resistance after CDK4/6 inhibitor progression in advanced breast cancer. Read More ›

Discover how oral SERDs and innovative combination therapies are reshaping breast cancer treatment, offering new hope for patients with advanced and resistant disease. Read More ›

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Read More ›

Page 2 of 16

Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications